Drug Profile


Alternative Names: CS 610; Galardin; GM 6001

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Florida
  • Developer Arriva Pharmaceuticals; Quick-Med Technologies
  • Class Antineoplastics; Eye disorder therapies; Indoles; Small molecules
  • Mechanism of Action Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Chemical burns
  • Discontinued Cancer; Chronic obstructive pulmonary disease; Corneal ulcer; Diabetic retinopathy

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Chemical-burns in USA (Topical)
  • 31 Dec 2009 Ilomastat is still in preclinical trials for Chemical burns in USA
  • 07 Apr 2008 Ilomastat is still in Preclinical trials for Chronic obstructive pulmonary disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top